Podcasts about clinical trials

Jennifer J. Brown is a scientist, a writer, and a mother who never got the luxury of separating those roles. Her memoir When the Baby Is Not OK: Hopes & Genes is a punch to the gut of polite society and a medical system that expects parents to smile through trauma. She wrote it because she had to. Because the people who gave her the diagnosis didn't give her the truth. Because a Harvard-educated geneticist with two daughters born with PKU still couldn't get a straight answer from the very system she trained in.We sat down in the studio to talk about the unbearable loneliness of rare disease parenting, the disconnect between medical knowledge and human connection, and what it means to weaponize science against silence. She talks about bias in the NICU, the failure of healthcare communication, and why “resilience” is a lazy word. Her daughters are grown now. One's a playwright. One's an artist. And Jennifer is still raising hell.This is a conversation about control, trauma, survival, and rewriting the script when the world hands you someone else's lines.Bring tissues. Then bring receipts.RELATED LINKS• When the Baby Is Not OK (Book)• Jennifer's Website• Jennifer on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

It's not always easy to participate in a clinical trial.  Even if you want to, how do you get the time off from work?  Starting in 2025, thanks to the Foundation for Sarcoidosis Research, there is a provision called the FMLA Clarification, which essentially states that you can participate without fear of losing your job.  In this episode of the FSR Sarc Fighter Podcast, Dr. Ennis James, a sarcoidosis researcher and physician at the Medical University of South Carolina, and Tricha Shivas, Chief of Staff and Strategy at FSR join me to talk about how difficult life can be for patients.  Dr. James shares a real-life story about a woman who fought to stay in a trial after problems arose at work.   SHOW NOTES OP-ED by Dr. Ennis James in STAT: https://www.statnews.com/2025/09/24/clinical-trial-patient-fmla-foundation-sarcoidosis-research-job-security/ SHRM: https://www.shrm.org/ FSR News Release: https://www.stopsarcoidosis.org/coalition-to-transform-clinical-trial-engagement-launches-champions-for-change-pto-initiative/ More from FSR: https://www.stopsarcoidosis.org/fsr-receives-confirmation-from-the-department-of-labor-ensuring-patient-access-to-fmla-for-participation-in-clinical-trials/ MORE FROM JOHN: Cycling with Sarcoidosis http://carlinthecyclist.com/category/cycling-with-sarcoidosis/ Do you like the official song for the Sarc Fighter podcast?  It's also an FSR fundraiser! If you would like to donate in honor of Mark Steier and the song, Zombie, Here is a link to his KISS account.  (Kick In to Stop Sarcoidosis)  100-percent of the money goes to the Foundation.  https://stopsarcoidosis.rallybound.org/MarkSteier The Foundation for Sarcoidosis Research https://www.stopsarcoidosis.org/ Donate to my KISS (Kick In to Stop Sarcoidosis) fund for FSR  https://stopsarcoidosis.rallybound.org/JohnCarlinVsSarcoidosis?fbclid=IwAR1g2ap1i1NCp6bQOYEFwOELdNEeclFmmLLcQQOQX_Awub1oe9bcEjK9P1E My story on Television https://www.stopsarcoidosis.org/news-anchor-sarcoidosis/ email me  carlinagency@gmail.com #sarcoidosis #sarcoidosisawareness #fmla #fmlaclarification                    

This episode of Standard Deviation features Oliver Bogler in conversation with Dr Na Zhao, a cancer biologist caught in the crossfire of science, politics, and survival. Na's life reads like a brutal lab experiment in persistence.She grew up in China, lost her mother and aunt to breast cancer before she turned twelve, then came to the United States to chase science as both an immigrant and a survivor's daughter. She worked two decades to reach the brink of independence as a cancer researcher, only to watch offers and grants vanish in the political chaos of 2025.Oliver brings her story into sharp focus, tracing the impossible climb toward a tenure-track position and the human cost of a system that pulls the ladder up just as people like Na reach for it. This conversation pulls back the curtain on the NIH funding crisis, the toll on early-career scientists, and what happens when personal tragedy fuels professional ambition.Listeners will walk away with a raw sense of how fragile the future of cancer research really is, and why people like Na refuse to stop climbing.RELATED LINKSDr Zhao at Baylor College of MedicineDr Zhao on LinkedInDr Zhao's Science articleIndirect Costs explained by US CongressFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The emerging therapy improved vision for some participants in an earlier clinical trial.

Dr. Hoffman continues his conversation with Dr. Julie Faitg, a mitochondrial biologist and senior manager of Applied Research and Regulatory Affairs at Timeline. 

In this episode of the Intelligent Medicine podcast, Dr. Ronald Hoffman delves into the critical role of mitochondria in overall health with a particular emphasis on skincare with Dr. Julie Faitg, a mitochondrial biologist and senior manager of Applied Research and Regulatory Affairs at Timeline. The discussion highlights the broad impacts of mitochondrial health on lifestyle, diet, sleep, exercise, and psychological well-being. Focusing specifically on Urolithin A (MitoPure), they explore its promising benefits for muscle strength, endurance, and skin health through cellular renewal processes like mitophagy. Dr. Faitg emphasizes the clean formulation and clinical effectiveness of Timeline's various supplements and skincare products, underscoring their role in extending healthspan and rejuvenating skin from the outside in. The episode provides practical insights on product usage and the broader implications of mitochondrial science for anti-aging and wellness.

Send us a textChristy Kestner, PhD, joins Erich Schramm, MD to discuss her journey from bench scientist to medical communicator. She talks about the importantce of spreading knowledge far and wide, particularly in the current era of massive misinformation. The duo talk about the problem of keeping medical and scientific information in silos and how communicators like Christy Kestner can help other scientists and doctors communicate more effectively with the public and patients alike. Christy Kestner introduces her work at Endosymbiont and her platform at Brain and Beyond to help people understand the complex world of medicine. Dr. Schramm then asks about some of the upcoming neuroscience research, including with brain computer interfaces, ALS, and Alzheimer's treatments.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Katie Henry has seen some things. From nonprofit bootstraps to Big Pharma boardrooms, she's been inside the machine—and still believes we can fix it. We go deep on her winding road from folding sweaters at J.Crew to launching a vibrator-based advocacy campaign that accidentally changed the sexual health narrative in breast cancer.Katie doesn't pull punches. She's a born problem solver with zero tolerance for pink fluff and performative empathy. We talk survivor semantics, band camp trauma, nonprofit burnout, and why “Didi” is the grandparent alter ego you never saw coming.She's Murphy Brown with a marimba. Veronica Sawyer in pharma. Carla Tortelli with an oncology Rolodex. And she still calls herself a learner.This is one of the most honest, hilarious, and refreshingly real conversations I've had. Period.RELATED LINKS:Katie Henry on LinkedInKatie Henry on ResearchGateLiving Beyond Breast CancerNational Breast Cancer CoalitionFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode of the Intelligent Medicine podcast is a deep dive into the complexities of Lyme disease and other tick-borne illnesses. Nicole Bell, the CEO of Galaxy Diagnostics and author of “What Lurks in the Woods,” details the challenges of diagnosing tick-borne diseases, the limitations of current diagnostic tests, and the controversy around treatment methodologies. Nicole shares her personal journey that led her to this field after her husband was misdiagnosed with early-onset Alzheimer's, which was later revealed to be caused by advanced Lyme disease. They also discuss new diagnostic techniques, the importance of personalized treatment plans, and ongoing advocacy efforts to improve awareness and research funding for Lyme disease.

Dr. Hoffman continues his conversation with Nicole Bell, the CEO of Galaxy Diagnostics and author of “What Lurks in the Woods.” 

Durable vision improvements were also observed out to 18 months for previously dosed adult patients in the trial.

In this episode of the ThinkData Podcast, I sit down with Ro Wickramasinghe, Global Head of Business Development at Pi Health, the AI platform rethinking how clinical trials are run.We explore:

In this episode, we explore how Explainable AI (XAI) is revolutionizing drug development, rare disease research, and precision medicine.Our guest, Frédéric Parmentier, Vice President of Data Science at Ariana Pharma, shares how their Explainable Artificial Intelligence (XAI) platform, KEM (Knowledge Extraction and Management), helps uncover critical biomarker signatures in small cohort clinical trials. Unlike traditional black box AI models, XAI delivers transparent, interpretable results that regulators and clinicians can trust—making it a game-changer for early-phase drug development, rare disease trials, and personalized medicine.We dive into:Why Explainable AI in clinical trials is essential for regulatory acceptance and scientific validation.How XAI can identify biomarkers of best responders in cohorts as small as 20–100 patients.Real-world examples where AI revealed insights that traditional statistics missed.The future of AI in drug development, precision medicine, and rare disease research.The difference between black box AI vs. Explainable AI in healthcare and why transparency matters.If you work in biopharma, clinical research, AI-driven healthcare, or drug discovery, this episode will give you powerful insights into how XAI can accelerate development, reduce trial failures, and enable personalized treatment strategies.About the PodcastAI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.This show brings together leading experts and changemakers to demystify AI and show how it's being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI's role in social good, this podcast offers valuable insights.AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget. As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses. This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more. Dr. Andree Bates LinkedIn | Facebook | Twitter

Send us a textDr. Michael Koren joins Kevin Geddings in talking about the start of flu season and the benefits of getting a flu shot through the clinical trials process. The doctor explains that modern flu shot trials don't use a placebo, they compare two different types of flu shot but everyone is protected. The two also discuss some of the rumors and mysteries surrounding flu shots, including why patients 65 and up sometimes get offered a different vaccine than those younger.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

With David Erlinge and Sasha Koul, Lund University, Lund - Sweden Read the European Heart Journal paper Read the European Heart Journal editorial

Send us a textWhat if you could hold in your hands a roadmap to the most influential studies that have shaped modern neonatology? In this special episode of The Incubator Podcast, Ben and Daphna sit down with Dr. John Zupancic, Dr. Susanna Hay, and Dr. Roger Soll to discuss the release of their new book, 50 Studies Every Neonatologist Should Know. Together with their co-editors Dr. Barbara Schmidt and Dr. Haresh Kirpalani, the team has distilled decades of neonatal research into an accessible, thoughtfully structured volume designed to guide clinicians, trainees, and educators.The conversation explores the motivation behind the book, the editorial process of selecting just 50 landmark trials from thousands, and the importance of revisiting historical studies to understand how evidence has evolved over time. From the groundbreaking DART trial to the early work of pioneers like Bill Silverman, the authors emphasize not only the science but also the stories, challenges, and human insights that lie behind each study.Whether you are a seasoned neonatologist or just beginning your training, this episode provides a behind-the-scenes look at a project that brings clarity and context to evidence-based practice.

Osteosarcoma Webinar Series: Amy Armstrong, MD, a pediatric oncologist at Siteman Kids, joins us on OsteoBites to discuss an open-label, cohort-sequential dose-escalation and dose-confirmation Phase 1/2 clinical trial to evaluate the safety and efficacy of domatinostat in combination with sirolimus in adolescents and adults with relapsed, refractory sarcoma and osteosarcoma. She will review background, patient selection, treatment plan and study calendar for this clinical trial.Dr. Amy Armstrong is a pediatric oncologist who directs the Solid Tumor Program at Siteman Kids, affiliated with St. Louis Children's Hospital, as well as co-directs the Adolescent and Young Adult Sarcoma Program in collaboration with Siteman Kids and Siteman Cancer Center. She is an Associate Professor of Pediatrics at Washington University in St. Louis and has research interests in Neurofibromatosis Type 1-related plexiform neurofibromas, renal tumors, and sarcomas found most commonly in the adolescent and young adult population. Dr. Armstrong serves as site Principal Investigator for the Children's Oncology Group, Neurofibromatosis Clinical Trials Consortium and National Pediatric Cancer Foundation and is invested in conducting and developing clinical trials to serve a diverse range of solid tumors in both the upfront and relapsed setting.

Today I get to talk with Lakshmi Grama, former Associate Director for Dissemination and Digital Communications at the National Cancer Institute. She shares stories of early days at NCI, bringing everyone to the table, and power dynamics in health information. Communication about clinical trials is a very specialized part of health communication, but stories from […] The post Lakshmi Grama on how people affected by cancer helped shape Cancer.gov's Clinical Trials Information (Part 1) appeared first on Health Communication Partners.

In this episode, we take a deep dive into the state of the treatment pipeline for bleeding disorders. From the way clinical trials are structured to what's actually available for different conditions, we examine both the promise and the reality of innovation in this space. Recorded live at the NBDF Bleeding Disorders Conference, we join Mike Recht, MD, PhD, Chief Science and Medical Officer of NBDF, for a “research posters walk & talk” to explore what's happening right now — and why so many promising treatments never make it to market. Guests: Mike Recht, MD, PhD Maria Santaella, PhD(c), MSN, RN-BC, CPHON Samantha Carlson, LMSW   Senior Advisor: Donna DiMichele, MD   Hosted by: Patrick James Lynch   Written by: Kay Vermeil   Featured Advertiser: Sanofi   Subscribe to the Global Hemophilia Report   Show Notes:   Join Kevin as he shares about his journey with hemophilia and the hurdles he faced in communicating with friends, family, and healthcare providers about his condition. He highlights how hemophilia affects far more than just physical health — and why honest, open conversations that focus on the full patient experience, not just symptoms, are so essential.   Click here to watch his story: https://www.youtube.com/watch?v=3v1cCTbhClA&list=PLmqBxf22n4lNK82h3QZ-9YlpIjYdzDOer&index=5   Sanofi's Global Hemophilia Survey uncovers significant care gaps and emotional challenges faced by patients and caregivers. Learn how improving health literacy and fostering better patient-provider communication are essential to addressing these inequities. Explore the findings and see how Sanofi is driving health equity for the hemophilia community. Explore the survey findings here: Global Hemophilia Survey Page. Connect with the Global Hemophilia Report Global Hemophilia Report on LinkedIn Global Hemophilia Report on X/Twitter Global Hemophilia Report on Facebook   Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on X/Twitter   

Welcome to The Peptide Podcast. In this episode, we're unpacking the latest on retatrutide and how it measures up against semaglutide and tirzepatide.  If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  https://pepties.com/partners/ We'll look closely at what the studies tell us so far — from overall weight loss to reductions in visceral fat and how much lean muscle mass is preserved. We'll also talk about where the evidence is solid, where it's still developing, and why cross-trial comparisons should be made with caution. What is retatrutide? So let's start with the basics—what is retatrutide? Retatrutide is a new type of weight-loss medication called a triple agonist. That sounds fancy, but what it really means is that it targets three hormone receptors in the gut and pancreas: GLP-1, GIP, and glucagon. Each of these plays a slightly different role in metabolism and appetite regulation. To break it down: GLP-1, which you might already know from drugs like semaglutide, mainly slows digestion, helps you feel full, and improves insulin sensitivity. GIP, which tirzepatide targets along with GLP-1, also helps regulate blood sugar and may improve how the body stores and burns fat. Retatrutide adds glucagon receptor activation on top of that, which seems to further boost fat burning. So how does this compare to semaglutide and tirzepatide? Semaglutide is a GLP-1-only drug, so it mainly works by reducing appetite and slowing gastric emptying. Tirzepatide is a dual agonist, hitting GLP-1 and GIP, which gives it a slightly stronger effect on blood sugar control and fat metabolism compared to semaglutide. Retatrutide goes one step further by adding glucagon activity, potentially giving more total fat loss. In other words, you can think of it like a spectrum: semaglutide hits one target, tirzepatide hits two, and retatrutide hits three—each additional receptor seems to enhance metabolic effects and fat loss in clinical trials. That's why people are excited about retatrutide, though it's still early, and we're waiting on larger studies to see exactly how it compares head-to-head with the others. And that's going to be key, since right now we don't have direct comparisons to other advanced therapies like semaglutide or tirzepatide in the published Phase 2 data. How does retatrutide compare to semaglutide and tirzepatide? Total body weight loss: Now let's put these three medications side by side and look at what the trials actually tell us about total body weight loss. Starting with retatrutide: in its Phase 2 obesity program, the numbers were unusually large, especially given the relatively short trial window. In the 48-week study, people on the higher doses—8 or 12 milligrams weekly—lost about 22 to 24% of their body weight on average. That's the result that really made headlines. It's worth noting that some trials report slightly different averages depending on the group studied—people with obesity but no diabetes versus people with type 2 diabetes—but across the board, that 48-week signal is consistently very strong. For comparison, let's step back to semaglutide at the 2.4 mg dose, which was tested in the pivotal STEP-1 trial. Over 68 weeks, participants lost about 15% of their body weight on average. That was a landmark finding when it was published in the New England Journal of Medicine—it essentially set the modern benchmark for what a GLP-1 monotherapy could do. Then we have tirzepatide, the dual GIP and GLP-1 agonist. The SURMOUNT-1 trial, which ran for 72 weeks, showed dose-dependent results: about 15% weight loss at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, compared to only around 3% with placebo. Other obesity studies with tirzepatide have backed this up, especially at the higher doses. And in head-to-head comparisons with semaglutide, tirzepatide has consistently come out on top. So if we zoom out: retatrutide's Phase 2 data suggest the greatest average reductions—over 22%—in less than a year. Tirzepatide follows closely behind with around 21% over 72 weeks. And semaglutide shows very meaningful, but smaller, weight loss of around 15% over a similar time frame. The big caveat here is that these aren't perfect apples-to-apples comparisons. The trials differed in their length, the types of patients enrolled—some had type 2 diabetes, some did not—their baseline weights, and even the way results were reported. Plus, retatrutide is still in Phase 2 for obesity, whereas semaglutide and tirzepatide already have large Phase 3 programs and real-world data backing them up. Visceral fat reduction: Next, let's talk about visceral fat reduction—that's the deep fat that surrounds organs like the liver, pancreas, and intestines. It's particularly important because high levels of visceral fat are strongly linked to cardiometabolic disease. Starting with retatrutide, one of the Phase 2 substudies used DEXA scans to measure body composition in detail. At the higher doses—8 and 12 milligrams per week—participants saw visceral fat drop by about 29 to 31% over 48 weeks. That's a very large relative reduction in under a year and one of the reasons people are excited about retatrutide's potential not just for weight loss, but also for improving long-term metabolic health. How does that compare to the other drugs? With semaglutide, we also have DEXA and imaging substudies from the STEP program and follow-up mechanistic work. These consistently show meaningful visceral fat reductions, along with improvements in the ratio of lean to fat mass. The difference is that semaglutide studies typically report VAT changes as “significant and clinically relevant,” but they don't always publish one clear headline number that's directly comparable to retatrutide's ~30%. In other words, semaglutide definitely lowers visceral fat, but depending on the study and population, the exact percentage looks different. For tirzepatide, we also have imaging-based data from the SURMOUNT trials and related body-composition studies. These show that the majority of weight lost is fat mass—including a significant portion of visceral fat. Some analyses report reductions on par with what's seen with GLP-1 therapies, while others suggest tirzepatide may push a bit further. But again, the actual percentages vary depending on whether the study used DEXA, CT, or MRI, and on who was enrolled. The big caveat here is that we don't yet have a head-to-head imaging study comparing all three drugs in the same population with the same methods. Retatrutide's ~30% visceral fat drop is certainly eye-catching, but without that kind of standardized comparison, it's hard to say definitively whether it's truly better than semaglutide or tirzepatide. Lean muscle mass preservation: Now let's shift to lean mass preservation, which is just as important as total weight or fat loss. Across all of the modern obesity drug trials, one thing has been consistent: most of the weight people lose is fat, but some lean tissue is lost too. That's expected whenever you're in a sustained calorie deficit. The question is how much muscle is preserved, and how the proportions break down. With retatrutide, the DEXA substudy showed something reassuring. Even though people lost a lot of total weight and fat, the proportion of lean mass lost compared to total weight loss was similar to what we see with other therapies. In other words, the drug seems to drive large fat reductions without causing disproportionate muscle loss. Interestingly, the absolute amount of lean tissue lost in kilograms was pretty stable across different doses, even though fat loss varied quite a bit. That suggests the extra weight loss with higher doses is really coming from fat, not muscle. Looking at semaglutide, the STEP trials with DEXA scans reported the same general pattern. People lost more fat than lean mass, and when you adjust for the total weight loss, body composition actually improved. In fact, some analyses showed a slight increase in the percentage of body weight that was lean tissue, even though the absolute lean mass in kilograms went down. So again, it's not that muscle isn't affected—it is—but fat loss makes up the majority of the change. For tirzepatide, the SURMOUNT body-composition studies found that about 75% of the weight lost is fat and about 25% is lean mass. That split is very similar to what was seen in the placebo groups, which means the drug isn't shifting the balance unfavorably. It preferentially reduces fat, while lean mass preservation is in the same ballpark as semaglutide and retatrutide. Now, here's the important nuance: lean mass on a DEXA scan isn't just skeletal muscle. It includes water, organ tissue, and other components. So if someone loses 3 or 4 kilograms of “lean mass,” we don't know how much of that is functional muscle versus water or smaller organ size. That's why these numbers can be misleading if you take them at face value. And this is where lifestyle comes in. Resistance training and adequate protein intake are critical alongside medication. Lifting weights or doing bodyweight resistance work helps preserve functional muscle, while getting enough protein—typically somewhere in the range of 0.8 to 1 gram per pound per day depending on age and activity—supports muscle repair and maintenance. Every trial we've seen shows that the best outcomes, in terms of maintaining strength and function, come from pairing these drugs with exercise and nutrition strategies. That way, the unavoidable lean mass changes have far less impact on long-term metabolic health and performance. Limitations, biases, and what's missing (the critical context). No large, peer-reviewed head-to-head trials (yet) comparing retatrutide with semaglutide or tirzepatide for the same endpoints using identical imaging protocols. Most comparisons are cross-trial and therefore imperfect. Retatrutide Phase-2 was often compared to placebo or dulaglutide (in the T2D DEXA substudy) rather than to semaglutide or tirzepatide. A head-to-head (planned/registered) study vs tirzepatide is listed on ClinicalTrials.gov but results are not published yet. Different populations & durations. Some retatrutide data come from cohorts that include people with T2D or NAFLD; semaglutide STEP trials were often in people with obesity (without diabetes) and run longer (68 weeks), while tirzepatide SURMOUNT trials ran to 72 weeks. These differences change the absolute and percent outcomes. Funding and reporting bias. Many of the early retatrutide analyses are industry-funded (Eli Lilly), which is standard for drug development, but it requires us to carefully read methods, endpoints, and completeness of reporting. Independent replication and Phase-3 confirmation matter. Imaging method variation. VAT reported by DXA vs MRI vs CT are not directly interchangeable. Some trials report VAT area, others percent change; that complicates cross-trial percent comparisons.  Thanks for listening to The Peptide Podcast. If today's episode resonated, share it with a friend. Until next time, be well, and as always, have a happy, healthy week.

Send us a textTriple-board certified psychologist Dr. Heather Luing joins Dr. Erich Schramm to talk about depression. Major depressive disorder affects one in five Americans and ranks among the most disabling conditions worldwide. In spite of this, treatments for depression can be unsatisfying or ineffective for up to 1/3 of patients. The doctors discuss the symptoms, treatments, and biological underpinnings of depression. They move to advances in medications and devices and the possibilities that clinical trials hold for the not-too-distant future, including non-medical solutions like Transcranial Magnetic Stimulation and Vagus Nerve Stimulation for medication-resistant patients.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

How can we fix a healthcare system that has too often overlooked women? In this episode, host Elaine Hamm, PhD, speaks with Georgie Kovacs, MBA, Founder and CEO of Fempower Health, about her mission to empower women through evidence-based information and community support. Georgie shares her journey from personal experience with endometriosis to building a trusted platform that connects women with leading experts. Together, Elaine and Georgie dig into the history—and ongoing challenges—of women's inclusion in clinical trials, the gaps in data that still shape care today, and why patient advocacy and systemic change are more critical than ever. In this episode, you'll learn: Why women were historically excluded from clinical trials—and the consequences still felt today. How patient advocacy, informed consent, and inclusion can reshape women's healthcare. What biotech leaders, clinicians, and investors must consider when designing studies and funding women's health innovations. Tune in to hear Georgie's vision for transforming women's health from fragmented care into informed, empowered, and equitable solutions. Links: Connect with Georgie Kovacs, MBA, and check out Fempower Health. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Check out the Endometriosis Working Group and take the survey. Learn more about the Tulane Center of Excellence in Sex-Based Precision Medicine. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Remote Ischemic Preconditioning Prevents Acute Kidney Injury Following Coronary Angiography: The BRICK Randomized Clinical Trial.

The latest developments surrounding Ozempic and weight loss continue to generate major interest and headlines, especially with new research and high-profile figures like Oprah Winfrey sharing personal experiences. In the past week, new clinical trial data and ongoing cultural conversations have kept this topic at the forefront.Researchers have revealed that a daily pill version of semaglutide—the active ingredient in Ozempic—can deliver weight loss results comparable to injectables. According to reporting in The New England Journal of Medicine, participants in a 64-week trial who took oral semaglutide lost over 16 percent of their baseline body weight, while those on a placebo lost just 2.7 percent. More than a third of those on the Ozempic pill achieved at least a 20 percent weight reduction. These findings indicate that more convenient alternatives to weekly injections could soon be available for people seeking medical weight management. Cardiovascular risk factors and physical function also improved among those taking the new pill, further supporting its potential for broader approval later in the year.While Ozempic is widely recognized for its effect on appetite—helping users feel full sooner and eat less—the discussion about its effectiveness versus other weight loss methods also remains active. Recent clinical data suggest that surgery still leads to substantially greater average weight loss over time. At New York University, researchers found that patients receiving bariatric surgery lost about 25 percent of their body weight over two years, compared to approximately 5 percent for those sticking with GLP-1 agonists like Ozempic. Factors such as medication adherence and long-term commitment play a massive role in these outcomes. In fact, studies estimate that up to 70 percent of patients may discontinue their weight loss medications within the first year. Experts say this underscores the importance of treating obesity as a chronic and complex disease rather than seeking a one-size-fits-all solution.Oprah Winfrey continues to shape the public conversation about medical weight loss, drawing both criticism and admiration for her openness and candor this week. On her podcast, Oprah confirmed she has used a GLP-1 agonist—though not specifying Ozempic by name—to quiet her mind's “food noise” and help manage her weight. She explained that the drug's effect of mimicking a natural hormone made her realize many people are not waging an internal battle with cravings but simply respond to true hunger and fullness cues. For decades, Oprah says she blamed herself for her struggles, thinking thinness was a matter of willpower or discipline, only to learn that biological predisposition can override even the strongest effort.As she approaches her seventieth birthday, Oprah's primary focus is on maintaining her health and vitality, not just the numbers on the scale. She has emphasized that the medication is one tool in a regimen that includes rigorous exercise, structured meal times, hydration, and dietary principles. In a recent interview, she stressed that there's no shortcut: she hikes daily, counts Weight Watchers points, and drinks a gallon of water each day. Oprah encourages listeners to understand that obesity is a disease based in the brain, and that shame and blame are harmful and misguided. The backlash she faced for admitting she takes medication—some critics say it is the “easy way out”—reflects larger societal debates about medical interventions, with Oprah herself challenging that narrative by sharing her experience of hard work and self-acceptance.Medical experts interviewed in national outlets continue to say that GLP-1 drugs like Ozempic can help people lose between 15 to 20 percent of their body weight when paired with lifestyle changes like healthy eating and physical activity. They caution that success is not just about taking a weekly injection or pill but requires sustained adherence and behavioral support. Side effects like nausea, vomiting, and stomach pain remain a consideration, and patients are advised to consult closely with their health care providers.Meanwhile, innovation in obesity management is accelerating. The upcoming oral formulations of semaglutide and similar molecules could make therapy more accessible and acceptable to a wider population. However, newer approaches, like targeting metabolic pathways beyond appetite control, are on the horizon and may ultimately change how weight is managed over the long term.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

In this episode of IDEA Collider, we are joined by Alex Telford, a biotech founder, writer, and thinker based in the San Francisco Bay Area. As the co-founder of Convoke Bio, Alex discusses his journey from studying biochemistry at UCL to founding a company that develops software tools for streamlining biopharmaceutical workflows.The conversation dives into the impact of AI and language models on the biotech industry, addressing inefficiencies in drug development, and exploring the potential of synthetic biology and personalized medicine. The discussion also touches on the future of drug discovery, China's role in biotech, and the challenges of understanding neuroscience and consciousness. Don't miss this insightful discussion on the future of biopharma innovation! 00:00 Welcome to Idea Collider00:04 Introducing Alex Telford01:59 Alex's Journey from UCL to Convoke Bio05:29 The Mission and Work of Convoke Bio07:57 Challenges in Pharma Decision Making14:05 The Role of AI in Pharma18:26 Knowledge Management and AI27:58 Staying Updated in the Fast-Moving AI Field30:25 AI's Impact on Industry Economics31:38 AI in Clinical Trials and Drug Development35:56 China's Role in Drug Discovery39:24 Neuroscience and AI: Blurring the Lines46:05 Future Predictions in Pharma51:20 Addressing Cognitive Bias in Pharma53:13 Concluding Thoughts and Future Directions Keep up with Alex Telford;LinkedIn: https://www.linkedin.com/in/alexander-telford/Website: atelfo.github.ioX: https://twitter.com/atelfoSubstack: atelfo.substack.com Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

FDA announces crackdown on misleading TV drug ads, influencers, online drug dispensaries; What's a “twisted colon”? Doctors often jump the gun in prescribing ADHD meds to young kids before behavioral fixes; A new era in skincare powered by urolithin A.

Let's say you or a family member wants to participate in a clinical trial, but the boss doesn't want you to have the time off because of extra visits to the doctor's office. Under new rules spearheaded by the Foundation for Sarcoidosis Research, companies must now allow patients time away from the job without fear of losing their employment.  In this special edition of the FSR Sarc Fighter Podcast, FSR CEO Mary McGowan joins me, along with Emily Dickens, Chief of Staff, Head of Government Affairs, and Corporate Secretary for Society for Human Resources Management.  Together they will walk us through the new guidelines for HR departments when it comes to allowing employees to participate in clinical trials.  @SHRM #SHRM #humanresources #clinicaltrial  Show Notes SHRM: https://www.shrm.org/ FSR News Release: https://www.stopsarcoidosis.org/coalition-to-transform-clinical-trial-engagement-launches-champions-for-change-pto-initiative/ More from FSR: https://www.stopsarcoidosis.org/fsr-receives-confirmation-from-the-department-of-labor-ensuring-patient-access-to-fmla-for-participation-in-clinical-trials/ MORE FROM JOHN: Cycling with Sarcoidosis http://carlinthecyclist.com/category/cycling-with-sarcoidosis/ Do you like the official song for the Sarc Fighter podcast?  It's also an FSR fundraiser! If you would like to donate in honor of Mark Steier and the song, Zombie, Here is a link to his KISS account.  (Kick In to Stop Sarcoidosis)  100-percent of the money goes to the Foundation.  https://stopsarcoidosis.rallybound.org/MarkSteier The Foundation for Sarcoidosis Research https://www.stopsarcoidosis.org/ Donate to my KISS (Kick In to Stop Sarcoidosis) fund for FSR  https://stopsarcoidosis.rallybound.org/JohnCarlinVsSarcoidosis?fbclid=IwAR1g2ap1i1NCp6bQOYEFwOELdNEeclFmmLLcQQOQX_Awub1oe9bcEjK9P1E My story on Television https://www.stopsarcoidosis.org/news-anchor-sarcoidosis/ email me  carlinagency@gmail.com #sarcoidosis #sarcoidosisawareness               

On this month's Time for a Check Up Sean Sullivan talked to Southern Cancer Center's Karla Childers about Clinical Trials.  Clinical trial are important to test medications that can help in the future!  How does it work??  Listen here:

Send us a textDr. Michael Koren joins Kevin Geddings to discuss the pivotal role imaging has played in diagnosis and understanding of various diseases. Dr. Koren notes that before the science of imaging, the only way to see what was going on inside the body was with a knife. They then discuss some of the newest applications of imaging and how the use of CT scans and amyloid PET scans can see inside the heart and arteries to see how a disease is progressing or the effectiveness of new medications.They talk about the progress that has been made and how we are able to see what's happening, but note that access to these imaging technologies is not evenly available and that sometimes cost or insurance can get in the way of healthcare access. Dr. Koren then points out that clinical research may offer some patients a way for some patients to access these imaging technologies outside of the traditional healthcare system if they have risks or signs of diseases being studied.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Welcome back to Ozempic Weightloss Unlocked, the podcast where we dive into the latest news and analysis about one of the most talked-about treatments for weight loss and metabolic health.Let us jump right in with some breaking research. According to The Lancet Diabetes and Endocrinology, new clinical trial data shows that a triple-dose of Ozempic, meaning 7.2 milligrams weekly, resulted in almost nineteen percent average weight loss in adults without diabetes. That is a substantial jump compared to the sixteen percent with the standard 2.4 milligram dose, and only around four percent with a placebo. Nearly half of those on the higher dose lost at least twenty percent of their body weight, and a third saw weight reductions of twenty-five percent or more. Even among adults with type 2 diabetes, the higher dose achieved thirteen percent weight loss, compared to ten percent with the lower dose. Waistlines, blood pressure, blood sugar, and cholesterol all improved on the higher dose. Safety remained solid, with the most common side effects being manageable nausea and diarrhea that usually settled down over time. Importantly, there was no increase in serious adverse events.Now, for lifestyle impacts and long-term use. A population-wide study presented at the European Association for the Study of Diabetes reports that half of people who start Ozempic for weight loss stop taking it within a year. Cost is a major factor, with the lowest dose costing around two thousand Euros a year in some areas. Younger adults and people from lower income neighborhoods were far more likely to discontinue, likely due to financial barriers. Adverse effects like nausea, and pre-existing conditions, played a role as well. The study found that men were more likely to stop early than women, and adherence was especially hard for those with a history of psychiatric conditions or chronic illness. That is concerning, since people with these conditions often need the benefits the most. Once people stop the medication, weight is often regained, showing just how important it is to find sustainable approaches to weight management.On the topic of who benefits most, a study in Frontiers in Clinical Diabetes and Healthcare highlighted that emotional eating can reduce the effectiveness of Ozempic. The medication is best for people who overeat due to external cues like the smell or appearance of food, rather than for those who eat in response to boredom, anxiety, or sadness. Health experts now recommend that healthcare providers assess a person's relationship with food before prescribing Ozempic or its counterparts. If emotional eating is a primary issue, psychological support may be necessary alongside medication.For those worried about cardiovascular risks, the REACH study presented at the annual meeting of the European Association for the Study of Diabetes confirmed that Ozempic stands out for reducing cardiovascular risk, even among those with multiple chronic conditions. Large-scale, real-world data reinforce its value, particularly in older populations who often have comorbidities like heart disease.Let us also touch on a warning that has emerged: rapid weight loss with medications like Ozempic can cause muscle loss, particularly in women and older adults. While the fat loses fast, it is essential to protect muscle mass with diet and exercise. Experts stress that lifestyle habits—good nutrition, adequate sleep, and physical activity—remain crucial for long-term results, even when taking medication.To sum up, Ozempic continues to make headlines for its effectiveness, but sticking with the medication is a challenge for many due to cost, side effects, and complex eating habits. Emotional and physical health both need to be addressed for the best outcomes. As always, open discussion with healthcare professionals about individual goals, potential barriers, and long-term maintenance is vital.Thank you for tuning in to Ozempic Weightloss Unlocked. Make sure to subscribe so you never miss an episode. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Ann Collins, PA, Blood Cancer United, Washington, DC, Kelly Laschinger, MSN, RN, CPNP, CPHON, Blood Cancer United, Washington, DC, Sarah K. Tasian, MD, Children's Hospital of Philadelphia, Philadelphia, PA Recorded on September 9, 2025 Ann Collins, PA Project Leader, Pediatric Acute Leukemia Master Clinical Trial (PedAL) Blood Cancer United Washington, DC Kelly Laschinger, MSN, RN, […]

EP. 231:  On this episode we're digging into one of the most exciting frontiers in cellular medicine: how Urolithin A, a powerful compound, supports mitochondrial health and slows the effects of aging at the cellular level. If you've been feeling low energy, dealing with inflammation, or noticing your strength and resilience aren't what they used to be, this episode is packed with science-backed insights to help recharge your body from the inside out. My guest today is Dr. Brad Currier, PhD, Manager of Clinical Trials at Timeline, who's leading the way in Urolithin A research. We're talking muscle metabolism, brain health, immunity, and how this prebiotic compound could be a total game changer for longevity and overall vitality. → Head to timeline.com/DRTYNA to get started & Use code DRTYNA at checkout to receive 20% off today!  Topics Discussed: → What is Urolithin A and how does it help mitochondria? → How does Urolithin A support muscle and metabolism? → How are postbiotics, gut health, and GLP-1s connected? → What does Mitopure research show for immunity and brain health? → How can you use Timeline's Urolithin A daily? Sponsored By: →  Head to timeline.com/DRTYNA to get started & Use code DRTYNA at checkout to receive 20% off today!  On This Episode We Cover:  → 00:00:00 - Introduction  → 00:01:19 - Understanding Urolithin A  → 00:05:24 - Mitochondrial health  → 00:09:08 - Mitochondrial lifecycle  → 00:11:08 - Muscular growth & health  → 00:14:21 - Mitopure research  → 00:17:50 - Postbiotics & the gut microbiome  → 00:22:14 - GLP1s & the gut  → 00:26:31 - Gut rehabilitation  → 00:28:03 - Aging  → 00:31:26 - High protein diets & strength training  → 00:34:45 - Aging + muscle strength  → 00:39:34 - Mitopure, HRT, + stacking  → 00:46:21 - Skincare + topicals  → 00:49:25 - Immune health + inflammation → 00:52:37 - Summary  → 00:56:27 - Trying Timeline!  Show Links:  → Dr. Tyna's Strength Corner Further Listening:  → EP. 196 | The Answer Is The Gym | Quick + Dirty → Strength Training Playlist  Check Out Timeline →  Head to timeline.com/DRTYNA to get started & Use code DRTYNA at checkout to receive 20% off today!  Disclaimer: Information provided in this podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional, or any information contained on or in any product. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before taking any medication or nutritional, herbal or other supplement, or using any treatment for a health problem. Information provided in this blog/podcast and the use of any products or services related to this podcast by you does not create a doctor-patient relationship between you and Dr. Tyna Moore. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease.

Clinical research is critical to the development of life saving treatments. And ACCC has long supported equitable access to clinical trials, including efforts to ensure that these trials reflect the diversity of the populations they serve. ACCC has made the Just ASK™ Training Program and Site Self-Assessment available free-of-charge to help research sites address barriers to participation in cancer clinical trials among racial and ethnic populations. In this episode, CANCER BUZZ facilities a candid conversation with Glyniss Redman, who received treatment at Gibbs Cancer Center and Research Institute for multiple myeloma, and 2 members of her cancer treatment team: clinical research coordinator Audrianna Carrington and oncologist hematologist Dr. Tondre Buck, about overcoming barriers, ensuring shared decision-making, and improving the inclusion of historically underrepresented groups in clinical trials.   “If you look at cancers in general, treatments have gotten better over the years in almost every category, and we wouldn't be here if it wasn't for clinical trials.” – Tondre Buck, MD   “We're playing the long game here. Some of the information or this research may not be about me. This is about our future generation…so this is a legacy game for me…This is what I'm doing with my [one] wild and precious life. I want to be here as long as I possibly can, but I also want my offspring: my children, my grandchildren, and my great grandchildren to be here as well and [to] have a better experience as far as health care and cancer.” – Glyniss Redman   “We do have to talk about past unethical experimentation and research in order for us to better prepare how we're going to go forward…[transportation] is one barrier that we are tackling. You know, we don't want to put that stress on the patients who have to choose between gas, their physician visit, their food, or their medicine for the day. So that is a huge barrier, and you really want that population to be represented on the trial, because rural populations tend to have higher cancer rates.” – Audrianna Carrington   Tondre Buck, MD Oncologist Hematologist Gibbs Cancer Center and Research Institute Spartanburg, SC   Audrianna Carrington Clinical Research Coordinator Gibbs Cancer Center and Research Institute Spartanburg, SC   Glyniss Redman Poet and Patient with Multiple Myeloma   Resources:   The Just ASK™ Training Program, Site Self-Assessment, and Training Facilitation Guide   ACORI Call to Action Summit   Clinical Research Terms Glossary   Increasing Clinical Trial Accrual Through the Implementation of a Clinical Trials Navigator   Gibbs Cancer Center and Research Institute   Cancer Moonshot Biobank   National Estimates of the Participation of Patients With Cancer in Clinical Research Studies Based on Commission on Cancer Accreditation Data   TalkAboutTrials.com

More options, more questions. Get clarity on patient selection and optimizing adjuvant cyclin-dependent kinase cyclin-dependent kinase (CDK)4/6 inhibitor therapy. Credit available for this activity expires: 9/16/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002908?ecd=bdc_podcast_libsyn_mscpedu

You're living with MS, and maybe you're thinking about participating in an MS clinical trial. But how do they work? Are they safe? What's the difference between Phase 1, 2, and 3 trials? What are the real patient risks and benefits of participating in a clinical trial? In this special episode of RealTalk MS, we're getting answers to those questions and so much more from my guest, Dr. Aaron Boster. Dr. Boster is the founder of the Boster Center for Multiple Sclerosis in Columbus, Ohio, where he brings over 20 years of experience as an MS clinician. Dr. Boster has also  participated in more than 65 clinical trials.  This special episode of RealTalk MS has been made possible through a generous grant from Sanofi. Sanofi has two ongoing Phase 3 clinical trials in MS studying Frexalimab, an investigational second-generation anti-CD40 ligand monoclonal antibody. If you are interested in learning more about these clinical trials, please visit SanofiStudies.com SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/ct1 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! Privacy Policy

In the Season 6 premiere of the Wealth Planning for the Modern Physician Podcast, host David Mandell welcomes Dr. Cynthia Matossian, an accomplished ophthalmologist, entrepreneur, and industry leader. Dr. Matossian shares her unique journey into medicine, starting from an initial interest in political science and international relations before ultimately discovering her passion for ophthalmology. She discusses the early challenges she faced in starting her own practice in 1987, particularly as a woman seeking financial backing in a male-dominated field, and the resilience and determination that fueled her success. Dr. Matossian reflects on the growth of her solo practice into a thriving multi-location enterprise with 14 physicians and over 90 employees. She emphasizes the importance of delegation, transparency, and staff empowerment in building an efficient, patient-focused practice. Her insights into practice management include implementing scribes to reduce physician burnout, investing in proper business education, and hiring skilled managers to bring structure and professionalism to the organization. She also highlights her personal approach to financial planning, beginning with small investments guided by a trusted advisor, which laid the foundation for long-term financial success. The conversation also explores Dr. Matossian's involvement in industry innovation, her leadership in clinical trials, and her founding of GPOptho, a group purchasing organization designed to help practices lower costs through collective buying power. She shares valuable advice for physicians considering private equity transactions, stressing the importance of preparing years in advance and selecting the right advisors. Ultimately, Dr. Matossian underscores the critical need for physicians to educate themselves on the business of medicine early in their careers, pairing clinical excellence with sound financial and practice management strategies. Learn more, including additional show notes, links, and detailed key takeaways, by visiting physicianswealthpodcast.com. Click here to get your FREE copy of our latest book, Wealth Strategies for Today's Physician!

Send us a textDr. Michael Myers joins Dr. Michael Koren for an interview about his physician journey from medical school to private practice, healthcare administration, health consulting, teaching, and writing. Dr. Myers talks about his serendipitous journey through many parts of the healthcare system and how this shaped his unique career path through medicine's changing landscape. The two also transition to modern discussions on vaccines and the need for credible information in this space.Dr. Myers is writing a book titled "The Vaccine Bible," to be published on Amazon: https://www.amazon.com/stores/author/B0BL15KXRV/allbooksBe a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

What happens when you hand a mic to the most extroverted, uncensored Gen Z career coach in New York? You get Olivia Battinelli—adjunct professor, student advisor, mentor, speaker, and unfiltered truth-teller on everything from invisible illness to resume crimes.We talked about growing up Jewish-Italian in Westchester, surviving the Big Four's corporate Kool-Aid, and quitting a job after 7 months because the shower goals weren't working out. She runs NYU Steinhardt's internship program by day, roasts Takis and “rate my professor” trolls by night, and somehow makes room for maple syrup takes, career coaching, and a boyfriend named Dom who sounds like a supporting character from The Sopranos.She teaches kids how to talk to humans. She's allergic to BS. And she might be the most Alexis Rose-meets-Maeve Wiley-mashup ever dropped into your feed. Welcome to her first podcast interview. It's pure gold.RELATED LINKS:Olivia Battinelli on LinkedInOlivia's Liv It Up Coaching WebsiteOlivia on InstagramNYU Steinhardt Faculty PageFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Sophie Sargent walked into the studio already owning the mic. A pandemic-era media rebel raised in New Hampshire, trained in Homeland Security (yep), and shaped by rejection, she's built a career out of DM'ing her way into rooms and then owning them. At 25, she's juggling chronic illness, chronic overachievement, and a generation that gets dismissed before it even speaks.We talk Lyme disease, Lyme denial, and the healthcare gaslighting that comes when you “look fine” but your body says otherwise. We dive into rejection as a career accelerant, mental health as content porn, and what it means to chase purpose without sacrificing identity. Sophie's a former morning radio host, country music interviewer, and Boston-based creator with a real voice—and she uses it.No fake podcast voice. No daddy-daughter moment. Just two loudmouths from different planets figuring out what it means to be seen, believed, and taken seriously in a system designed to do the opposite.Spoiler: She's smarter than I was at 25. And she'll probably be your boss someday.RELATED LINKSSophie on InstagramSophie on YouTubeSophie on LinkedInMedium article: “Redefining Rejection”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Martha Carlin, CEO and founder of the Bio Collective, details the significant influence of the microbiome on overall health. Martha discusses her unconventional path from accounting to microbiome research, sparked by her husband's Parkinson's diagnosis. Together, they explore the complex connections between gut health and diseases like Parkinson's, autism, and even Alzheimer's. Martha sheds light on groundbreaking research funded by NIH grants, the potential of machine learning and AI in understanding microbiome patterns, and the future prospects of personalized probiotics. Practical advice on maintaining a healthy microbiome, the impact of diet and exercise, and the intriguing intersections between gut health, neurochemistry, and systemic diseases are highlighted. The discussion also covers challenges in integrating microbiome research into clinical practice and potential future therapies.

Dr. Hoffman continues his conversation with Martha Carlin, CEO and founder of the Bio Collective.

Dr. Bradley Ong discusses the efficacy and safety of fremanezumab in adults with migraine and comorbid major depressive disorder. Show reference: https://jamanetwork.com/journals/jamaneurology/fullarticle/2833452 

Alternatives to surgery for venous insufficiency; AI “hallucinates” a never-before-seen brain region in crucial test; Vegetarian complains she is prone to falling; Could tinnitus be triggered by electromagnetic fields from lighting, devices? Cannabis derivatives improve sleep where drugs fail; A novel way of treating chronic nasal infections—with snot transplants! Mitochondrial dysfunction found to be the key to heart, brain problems.

In this podcast, experts Filipa Lynce, MD, and Rita Nanda, MD, discuss recent clinical trial and real-world data for antibody-drug conjugates (ADCs) used to treat triple-negative breast cancer (TNBC).

With Børge Nordestgaard and Anders Berg Wulff, Copenhagen University Hospital, Copenhagen - Denmark. Read the European Heart Journal - Cardiovascular Imaging paper Read the European Heart Journal - Cardiovascular Imaging editorial

NACA is a gene-agnostic, oral medication designed to preserve vision in people with retinitis pigmentosa and Usher syndrome.

This episode is sponsored by Invivyd, Inc.Marc Elia is a biotech investor, the Chairman of the Board at Invivyd, and a Long COVID patient who decided to challenge the system while still stuck inside it. He's not here for corporate platitudes, regulatory shoulder shrugs, or vaccine-era gaslighting. This is not a conversation about politics, but it's about power and choice and the right to receive care and treatment no matter your condition.In this episode, we cover everything from broken clinical pathways to meme coins and the eternal shame of being old enough to remember Eastern Airlines. Marc talks about what it means to build tools instead of just complaining, what Long COVID has done to his body and his patience, and why the illusion of “choice” in healthcare is a luxury most patients don't have.This conversation doesn't ask for empathy. It demands it.RELATED LINKSMarc Elia on LinkedInInvivyd Company SiteMarc's Bio at InvivydFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this interview, we sit down with John Tobin, Vice President of Clinical Operations at Splice Bio, to explore groundbreaking gene therapy research for Stargardt's disease and its potential impact on the blind and visually impaired community. John shares insights into Splice Bio's mission, how their innovative work could transform options for people living with vision loss, and what families, professionals, and supporters should know about emerging treatments. Stay tuned until the end for information on how to get involved in Splice Bio's clinical trials. Learn more here: www.splice.bio/clinical Or send an email to: Clinicaltrials@splice.bio #SpliceBio #genetherapy #clinicaltrials

Health care executive Shelli Pavone discusses her article "Why retail pharmacies are the future of diverse clinical trials," highlighting the urgent need to improve representation in clinical research. Shelli explains how barriers like mistrust, cost, and lack of access have historically excluded women and minority populations, leading to less effective treatments and persistent health disparities. She describes how leveraging retail pharmacies—trusted, accessible community hubs—can decentralize trials, expand recruitment, and boost retention. Listeners will gain practical insights on how pharmacies' existing infrastructure can be adapted for clinical research, why inclusivity matters for health outcomes, and how patient-centered innovation can reshape the future of medicine. Our presenting sponsor is Microsoft Dragon Copilot. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Now you can streamline and customize documentation, surface information right at the point of care, and automate tasks with just a click. Part of Microsoft Cloud for Healthcare, Dragon Copilot offers an extensible AI workspace and a single, integrated platform to help unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise—and it's built on a foundation of trust. It's time to ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

Meet Sarah Kennedy, CEO and founder of Calocurb, a revolutionary weight management product born from 15 years and $30 million of New Zealand government-backed science. If you've ever struggled with your relationship to food, including overeating, yo-yo dieting, or the constant battle with your willpower, this conversation will give you a refreshing new perspective.We explore the fascinating science of appetite suppression, from the evolutionary role of hunger and the “hindbrain” to the discovery that bitter compounds in hops can naturally stimulate GLP-1 and other satiety hormones. We also get into the history of how Scottish highlanders and Kalahari tribes used bitter plants for appetite control, how modern agriculture stripped bitters from our diet, and why restoring this missing piece could be a game-changer. If you've been looking for a natural, science-backed way to modernize your eating habits and find peace with food, this episode is for you. Visit calocurb.com/lukestorey and use code LUKE10 for 10% off your first order.DISCLAIMER: This podcast is for educational purposes only and not intended for diagnosing or treating illnesses. The hosts disclaim responsibility for any adverse effects from using the information presented. Consult your healthcare provider before using referenced products. This podcast may include paid endorsements.THIS SHOW IS BROUGHT TO YOU BY:KORRECT | Go to korrectlife.com/luke and use the code LUKE to get 15% off.FLFE | Try Focused Life-Force Energy for FREE for 15 days at lukestorey.com/flfe.SUNLIGHTEN | Save up to $600 when you go to lukestorey.com/sunlighten and use code LUKESTOREY in the pricing form.JUST THRIVE | Head to lukestorey.com/justthrive and use code LUKE20 to save 20%.MORE ABOUT THIS EPISODE:(00:00:00) The Science Behind Appetite Suppression(00:21:45) Clinical Trials, Hunger Science, & Alternatives to Injectables(00:38:37) Bitters, Dosing Protocols, & What's Actually in Calocurb(00:57:27) GLP-1 Side Effects, Vagus Nerve, & Fasting Use Cases(01:09:34) Sarah's Journey, Innovation, & Life LessonsResources:• Website: calocurb.com • Instagram: instagram.com/calocurb • Facebook: facebook.com/calocurbGLOBAL • X: x.com/Calocurb • TikTok: tiktok.com/@calocurb • YouTube: youtube.com/@calocurb • Shop all our merch designs at lukestoreymerch.com• Check out Gilded By Luke Storey: